Roivant Sciences Limited header image

Roivant Sciences Limited

ROIV

Equity

ISIN BMG762791017 / Valor 113331044

NASDAQ (2026-02-20)
USD 27.15-1.34%

Roivant Sciences Limited
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Roivant Sciences Limited is a biopharmaceutical company that focuses on developing and commercializing innovative therapies by leveraging technology to enhance drug development processes. The company aims to transform the pharmaceutical industry by integrating technology and data analytics into its operations, positioning itself as a pioneering PharmaTech entity. Roivant operates through a unique model of creating subsidiary companies, known as "Vants," each dedicated to specific therapeutic areas or technologies. This approach allows Roivant to efficiently manage and advance a diverse portfolio of drug candidates across various stages of development. The company is known for its strategic partnerships and collaborations, which help accelerate the development and commercialization of its therapies. Roivant's business strategy is centered on addressing unmet medical needs and improving patient outcomes through the application of cutting-edge technology and innovative drug development methodologies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

153%1Y
215%3Y
157%5Y

Performance

38.5%1Y
43.9%3Y
56.7%5Y

Volatility

Market cap

19431 M

Market cap (USD)

Daily traded volume (Shares)

4,679,868

Daily traded volume (Shares)

1 day high/low

11.78 / 11.37

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.38%USD 157.82
Dexcom Inc
Dexcom Inc Dexcom Inc Valor: 2107726
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%USD 73.08
Align Technology Inc
Align Technology Inc Align Technology Inc Valor: 1159441
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.33%USD 190.02
Insulet Corp
Insulet Corp Insulet Corp Valor: 2941247
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.89%USD 241.89
Henry Schein Inc
Henry Schein Inc Henry Schein Inc Valor: 83527
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.61%USD 79.57
NovoCure Limited
NovoCure Limited NovoCure Limited Valor: 29570025
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.26%USD 11.36
Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp Integra Lifesciences Holdings Corp Valor: 912247
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.33%USD 12.21
ICU Medical Inc
ICU Medical Inc ICU Medical Inc Valor: 940704
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.87%USD 157.03
CRISPR Therapeutics Ltd
CRISPR Therapeutics Ltd CRISPR Therapeutics Ltd Valor: 33408113
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.16%USD 53.46
Merit Medical Systems Inc
Merit Medical Systems Inc Merit Medical Systems Inc Valor: 951136
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%USD 82.21